Search results
Divi's Labs Q1 Preview: Low base, strong custom synthesis sales to aid profit growth
CNBC Awaaz· 25 minutes agoThe low base of the last fiscal and strong sales in the custom synthesis segment are expected to drive profit and revenue growth for Divi's. According to a Moneycontrol poll ...
Buy Sun Pharmaceutical Industries; target of Rs 1885: Prabhudas Lilladher
CNBC Awaaz· 4 hours agoPrabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the...
Share/Stock Market News - Latest NSE, BSE, Business News, Stock/Share Tips, Sensex Nifty, Commodity,...
CNBC Awaaz· 22 hours agoLatest India Stock/Share Market News, NSE, BSE, Global Market, Sensex Nifty. Live Business News headlines on IPO, Stock/Share tips, Personal Finance, Budget, Tax, Mutual Fund, Commodity Market ...
Accumulate Apar Industries; target of Rs 10,399: Prabhudas Lilladher
CNBC Awaaz· 7 hours agoPrabhudas Lilladher recommended accumulate rating on Apar Industries with a target price of Rs...
Bikaji Foods soars 8% to climb new peak; should you buy?
CNBC Awaaz· 2 hours agoBikaji’s execution in the high-growth packaged snacks industry remains ahead of its listed peers,...
SJS Enterprises hits 52-week high with 12% surge following robust Q1 earnings
CNBC Awaaz· 4 hours agoThe stock has surged more than 54 percent over the past six months, significantly outpacing the...
Tata Motors expects muted global demand, positive on domestic sales during festive season
CNBC Awaaz· 21 hours ago"Our strategy includes expanding our market share by introducing new models and proactively growing...
Buy ICICI Bank; target of Rs 1430: KR Choksey
CNBC Awaaz· 3 hours agoKR Choksey is bullish on ICICI Bank has recommended buy rating on the stock with a target price of Rs 1430 in its research report dated August 02, 2024.
Suzlon Energy stock gains 3% to hit near 52-week high; should you buy the multibagger?
CNBC Awaaz· 5 hours agoGradual building of momentum for higher execution, healthy order book, more healthy bid pipeline,...
Brokerages go neutral over Sun Pharma as uncertainty looms over Leqselvi launch
CNBC Awaaz· 7 hours agoBrokerages rolled out neutral calls for drugmaker Sun Pharmaceutical Industries after the company...